Eptifibatide | GlycoProtein IIb/IIIa Receptor Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / 整合素 / Eptifibatide/依替巴肽

Eptifibatide/依替巴肽 {[allProObj[0].p_purity_real_show]}

货号：A135064

Eptifibatide 是一种选择性的血小板糖蛋白 IIb/IIIa 受体拮抗剂，对血小板粘附有显著抑制作用。Eptifibatide 主要用于急性冠脉综合征的治疗和心脏介入手术中的抗血栓处理。

Eptifibatide/依替巴肽化学结构
CAS号：188627-80-7

Eptifibatide/依替巴肽 3D分子结构
CAS号：188627-80-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Eptifibatide/依替巴肽纯度/质量文件产品仅供科研

货号：A135064 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Nat. Electron., 2025, 8, 66-74. Ambeed. [ A100095 ]; • Adv. Mater., 2025, 2416621. Ambeed. [ A255324 , A420052 ]; • Adv. Mater., 2025, 2410493. Ambeed. [ A838608 ]; • Adv. Mater., 2025, 2420319. Ambeed. [ A106129 ]; 更多 >

整合素亚型比较

产品名称	Integrin ↓ ↑	纯度
Tirofiban	✔	99%+
ATN-161	✔	98%
RGD	✔	98%
A-205804	++ ICAM-1, IC50: 25 nM E-selectin, IC50: 20 nM	98%
SB-273005	++++ αvβ3 receptor, IC50: 1.2 nM αvβ5 receptor, IC50: 0.3 nM	98+%
Lifitegrast	✔	97%
Cilengitide TFA	+++ αvβ3 receptor, IC50: 4.1 nM αvβ5 receptor, IC50: 79 nM	99%+
Cyclo(-RGDfK) TFA	✔	99%+
Cyclo(RGDyK) trifluoroacetate	++ αVβ3 integrin, IC50: 20 nM	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Eptifibatide/依替巴肽生物活性

描述

Glycoprotein (GP) IIb/IIIa complexe is responsible for the formation of platelet aggregates and the adhesion of platelets to uncovered collagen fibers in the injured vessel wall. Eptifibatide is a potent antagonist of GPIIb/IIIa complex. It dose-dependently reduced the adhesion of collagen-activated platelets to a fibrinogen-coated surface with a concentration of 4-38μg/mL and the approximate IC₅₀ value was 11μg/mL. Eptifibatide at 4-52µg/mL reduced thrombin, collagen, and ADP-induced platelet aggregation in a concentration-dependent manner with estimated IC₅₀ values of 16, 25, and 27µg/mL for ADP, collagen and thrombin, respectively. In addition, eptifibatide at 52µg/mL reduced lysosome secretion induced by ADP, collagen and thrombin by 70, 60, and 50 %, respectively^[4]. Eptifibatide binds to GPIIb/IIIa complex with an K_D value of 120nM^[5]. In a mouse model of cecal slurry-induced sepsis, intravenous administration of eptifibatide (15µg/g, three times) resulted in lower sepsis scores and better survival when compared with vehicle-treated group.

Eptifibatide/依替巴肽动物研究

Dose

Rat: 2 mg/ml/kg^[3] (i.v.)

Administration

i.v.

Pharmacokinetics

Animal	Rats^[3]
Dose	2 mg/ml/kg
Administration	i.v.
T_1/2	0.131 h
T_max	2.00 min
AUC_0-73h	0.895 μg·h/ml
C_max	7.10 μg/ml

Eptifibatide/依替巴肽临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01994941	Acute Coronary Syndrome	Phase 4	Completed	-	Hong Kong ... 展开 >> Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority Hong Kong, Hong Kong 收起 <<
NCT01087723	Acute Coronary Syndrome	Phase 3	Completed	-	-
NCT01103440	Stable Angina	Phase 2	Completed	-	United States, New York ... 展开 >> Mount Sinai Medical Center New York, New York, United States, 10029 收起 <<

Eptifibatide/依替巴肽参考文献

[1]Schwarz M, Katagiri Y, et al. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther. 2004 Mar;308(3):1002-11.

[2]O'Shea JC, Tcheng JE. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. Expert Opin Pharmacother. 2002 Aug;3(8):1199-210.

[3]EPTIFIBATIDE

[4]Ciborowski M, Tomasiak M. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Acta Pol Pharm. 2009 May-Jun;66(3):235-42. PMID: 19645323.

[5]Moser M, Bertram U, Peter K, Bode C, Ruef J. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol. 2003 Apr;41(4):586-92. doi: 10.1097/00005344-200304000-00011. PMID: 12658060.

Eptifibatide/依替巴肽实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.20mL

0.24mL

0.12mL

6.01mL

1.20mL

0.60mL

12.02mL

2.40mL

1.20mL

Eptifibatide/依替巴肽技术信息

CAS号	188627-80-7
分子式	C₃₅H₄₉N₁₁O₉S₂
分子量	831.96
SMILES Code	O=C(O)C[C@H](NC(CNC([C@H](CCCCNC(N)=N)N1)=O)=O)C(N[C@@H](CC2=CNC3=C2C=CC=C3)C(N4[C@](CCC4)([H])C(N[C@H](C(N)=O)CSSCCC1=O)=O)=O)=O
MDL No.	MFCD05662245

别名
运输	蓝冰
InChI Key	CZKPOZZJODAYPZ-LROMGURASA-N
Pubchem ID	448812

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry, store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 250 mg/mL(300.49 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 50 mg/mL(60.1 mM)，配合低频超声助溶

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01994941	Acute Coronary Syndrome	Phase 4	Completed	-	Hong Kong ... 展开 >> Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority Hong Kong, Hong Kong 收起 <<
NCT01087723	Acute Coronary Syndrome	Phase 3	Completed	-	-
NCT01103440	Stable Angina	Phase 2	Completed	-	United States, New York ... 展开 >> Mount Sinai Medical Center New York, New York, United States, 10029 收起 <<
NCT01087723	-		Completed	-	-
NCT00476944	Coronary Artery Disease	Phase 4	Unknown	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Principal Investigator: Herman K Gold, MD Sub-Investigator: Aloke V Finn, MD Sub-Investigator: Igor F Palacios, MD Sub-Investigator: Robert C. Leinbach, MD Sub-Investigator: Kenneth Rosenfield, MD Sub-Investigator: Joseph Garasic, MD Sub-Investigator: Eugene Pomerantsev, MD, PhD Sub-Investigator: Ignacio Inglessis, MD Sub-Investigator: Farouc A Jaffer, MD, PhD Sub-Investigator: Andrew Maree, MD Sub-Investigator: George T Lau, MD Sub-Investigator: Owen C Raffel, MD Sub-Investigator: Leon M Ptaszek, MD Sub-Investigator: Vishal Gupta, MD Sub-Investigator: Maureen Daher, RN Sub-Investigator: Jae S Oh, BSc 收起 <<
NCT00250471	Unstable Angina	Phase 3	Completed	-	-
NCT03383393	-		Recruiting	December 5, 2019	Bulgaria ... 展开 >> Alexandrovska University Hospital Recruiting Sofia, Bulgaria, 1413 Contact: Liubomir Dosev, MD +359887493695 liubodosev@gmail.com 收起 <<
NCT03735979	Acute Ischemic Stroke	Phase 3	Not yet recruiting	April 2023	United States, Ohio ... 展开 >> University of Cincinnati Medical Center Not yet recruiting Cincinnati, Ohio, United States, 45267 Contact: Natalie Kreitzer, MD kreitzne@UCMAIL.UC.EDU 收起 <<
NCT01103440	-		Completed	-	-
NCT01433627	Acute Coronary Syndromes ... 展开 >> STEMI NSTEMI 收起 <<	Phase 3	Unknown	December 2015	-
NCT00289601	Angioplasty	Phase 4	Terminated(Sponsor support wit... 展开 >>hdrawn) 收起 <<	-	United States, Massachusetts ... 展开 >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 收起 <<
NCT00317395	Coronary Disease	Phase 2	Completed	-	-
NCT00250991	Stroke	Phase 1 Phase 2	Completed	-	United States, Arizona ... 展开 >> Barrow Neurologic Institute, St. Joseph's Hospital and Medical Center, 350 West Thomas Rd Phoenix, Arizona, United States, 85013 United States, California University of California, Los Angeles, UCLA Medical Center, 10833 Le Conte Ave. Los Angeles, California, United States, 90024 Santa Monica-UCLA Medical Center, 1250 16th Street Santa Monica, California, United States, 90404 St. John's Health Center, 1328 22nd St Santa Monica, California, United States, 90404 United States, Kentucky St. Elizabeth Medical Center South, One Medical Village Drive Edgewood, Kentucky, United States, 41017 Jewish Hospital Louisville, Jewish Hospital Healthcare Services Inc., 200 Abraham Flexner Way Louisville, Kentucky, United States, 40202 United States, Michigan University of Michigan, University of Michigan Health System, 1500 E. Medical Center Drive, TC B1354, Box 0303 Ann Arbor, Michigan, United States, 48109-0303 United States, New York Long Island Jewish, North Shore-Long Island Jewish Health System, 270-05 76 Avenue New Hyde Park, New York, United States, 11040 United States, Ohio The Christ Hospital, 2139 Auburn Ave. Cincinnati, Ohio, United States, 45219 University of Cincinnati, University Hospital, 234 Goodman Ave. Cincinnati, Ohio, United States, 45219 Good Samaritan Hospital, 375 Dixmyth Ave., Cincinnati, Ohio, United States, 45220-2489 The Jewish Hospital of Cincinnati, 4777 East Galbraith Rd, Cincinnati, Ohio, United States, 45236 Mercy Hospital, Western Hills, 3131 Queen City Ave. Cincinnati, Ohio, United States, 45238 Mercy Hospital, Mt Airy, 2446 Kipling Ave. Cincinnati, Ohio, United States, 45239 Bethesda North Hospital, 10500 Montgomery Rd Montgomery, Ohio, United States, 45242 United States, Pennsylvania Lehigh Valley Hospital, 1200 South Cedar Crest Blvd Allentown, Pennsylvania, United States, 18103 University of Pennsylvania, University of Pennsylvania Medical Center, 3400 Spruce Street Philadelphia, Pennsylvania, United States, 19104 United States, Rhode Island Brown University, Rhode Island Hospital, 593 Eddy St. Providence, Rhode Island, United States, 02903 United States, Tennessee Vanderbilt University, University Hospital, 1211 22nd Ave. S. Nashville, Tennessee, United States, 37232 收起 <<
NCT00061373	Ischemic Stroke	Phase 2	Completed	-	United States, District of Col... 展开 >>umbia Washington Hospital Center Washington, District of Columbia, United States, 20010 United States, Maryland National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 Suburban Hospital Bethesda, Maryland, United States, 20892 收起 <<
NCT00251823	Myocardial Infarction	Phase 3	Completed	-	Canada, Ontario ... 展开 >> University of Ottawa Heart Institute Ottawa, Ontario, Canada, K1Y 4W7 收起 <<
NCT01076764	Acute Coronary Syndrome	Phase 3	Completed	-	-
NCT00089895	Myocardial Ischemia ... 展开 >> Acute Coronary Syndrome 收起 <<	Phase 3	Completed	-	-
NCT00061373	-		Completed	-	-
NCT00370045	Coronary Artery Disease	Phase 4	Unknown	-	United States, Maryland ... 展开 >> Sinai Hospital Recruiting Baltimore, Maryland, United States, 21215 Contact: Kevin P Bliden, BS 410-601-4795 kbliden@lifebridgehealth.org Principal Investigator: Paul A Gurbel, MD Sub-Investigator: William Herzog, MD Sub-Investigator: Charles Cummings, MD Sub-Investigator: Ashwani Bassi, MD Sub-Investigator: Benjamin Dubois, MD 收起 <<
NCT01991366	-		Unknown	-	United States, District of Col... 展开 >>umbia Washington Hospital Center Washington, District of Columbia, United States, 20010 收起 <<
NCT01532544	Pneumonia	Phase 2	Terminated(Difficulty recruiti... 展开 >>ng patients, company closed down) 收起 <<	-	Denmark ... 展开 >> University hospital Copenhagen Copenhagen, Denmark, 2100 Vejle hospital Vejle, Denmark Finland Kuopio University Hospital Kuopio, Finland Tampere University Hospital Tampere, Finland, 33521 收起 <<
NCT00638976	Cardiovascular Disease	Phase 3	Completed	-	Italy ... 展开 >> Mediolanum Cardio Research Milan, Italy, 20144 收起 <<
NCT00111566	Coronary Artery Disease ... 展开 >> Myocardial Infarction 收起 <<	Phase 4	Completed	-	Canada, British Columbia ... 展开 >> Vancouver General Hospital Vancouver, British Columbia, Canada, V5Z 1L8 收起 <<
NCT00426751	Infarction, Myocardial	Phase 3	Completed	-	France ... 展开 >> GSK Investigational Site Alençon, France, 61014 GSK Investigational Site Bordeaux, France, 33076 GSK Investigational Site Caen Cedex 5, France, 14033 GSK Investigational Site Créteil, France, 94010 GSK Investigational Site Lille, France, 59037 GSK Investigational Site Melun, France, 77000 GSK Investigational Site Melun, France, 77007 GSK Investigational Site Nancy, France, 54000 GSK Investigational Site Ollioules, France, 83190 GSK Investigational Site Pau, France, 64046 GSK Investigational Site Perpignan, France, 66000 GSK Investigational Site Pessac Cedex, France, 33604 GSK Investigational Site Toulon, France, 83056 GSK Investigational Site Vandoeuvre Les Nancy, France, 54511 Germany GSK Investigational Site Freiburg, Baden-Wuerttemberg, Germany, 79106 GSK Investigational Site Heidelberg, Baden-Wuerttemberg, Germany, 69120 GSK Investigational Site Wuerzburg, Bayern, Germany, 97080 GSK Investigational Site Offenbach, Hessen, Germany, 63069 GSK Investigational Site Aachen, Nordrhein-Westfalen, Germany, 52074 GSK Investigational Site Dortmund, Nordrhein-Westfalen, Germany, 44137 GSK Investigational Site Moenchengladbach, Nordrhein-Westfalen, Germany, 41063 GSK Investigational Site Neuss, Nordrhein-Westfalen, Germany, 41464 GSK Investigational Site Ludwigshafen, Rheinland-Pfalz, Germany, 67063 GSK Investigational Site Homburg, Saarland, Germany, 66421 收起 <<
NCT00089895	-		Completed	-	-
NCT01863134	Non ST Elevation Myocardial In... 展开 >>farction 收起 <<	Phase 4	Completed	-	United States, New York ... 展开 >> Albert Einstein College of Medicine New York, New York, United States Poland First Department of Cardiac Surgery, Medical University of Silesia Katowice, Slaskie, Poland, 40-635 Center for Cardiovascular Research and Development, American Heart of Poland Katowice, Poland Department of Internal Medicine and Clinical Pharmacology Katowice, Poland First Department of Cardiology, Medical University of Silesia Katowice, Poland Division of Molecular Biology and Clinical Genetics, Jagiellonian University Medical College Krakow, Poland 收起 <<
NCT00426751	-		Completed	-	-
NCT01522417	Myocardial Infarction ... 展开 >> Acute Coronary Syndromes Unstable Angina 收起 <<	Phase 2	Recruiting	July 2019	United States, Florida ... 展开 >> Osceola Regional Medical Center Completed Kissimmee, Florida, United States, 34741 Northside Hospital Completed Saint Petersburg, Florida, United States, 33709 United States, Georgia Emory University Hospital Midtown Completed Atlanta, Georgia, United States, 30308 Emory University Hospital Completed Atlanta, Georgia, United States, 30322 North Georgia Heart Center Completed Gainesville, Georgia, United States, 30501 Redmond Regional Medical Center Recruiting Rome, Georgia, United States, 30165 Principal Investigator: Hector R Picon, MD Archbold Medical Center Completed Thomasville, Georgia, United States, 31792 United States, New York Lenox Hill Hospital Completed New York, New York, United States, 10075 United States, Oklahoma University of Oklahoma Health Sciences Center Recruiting Oklahoma City, Oklahoma, United States, 73104 Principal Investigator: Mazen Abu-Fadel, MD United States, Pennsylvania Doylestown Hospital Completed Doylestown, Pennsylvania, United States, 18901 Penn Presbyterian Medical Center Completed Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Centennial Heart Recruiting Nashville, Tennessee, United States, 37203 Principal Investigator: Brian K Jefferson, MD United States, Virginia Chippenham Hospital Recruiting Richmond, Virginia, United States, 23225 Principal Investigator: Michael L Arcarese, MD 收起 <<
NCT00719914	ST-Elevation Myocardial Infarc... 展开 >>tion 收起 <<	Phase 2	Terminated(Poor enrollment)	-	United States, Florida ... 展开 >> Cardiology Research Associates Ormond Beach, Florida, United States, 32174 United States, Michigan Crittenton Hospital Medical Center Rochester, Michigan, United States, 48307 United States, Ohio Mid Ohio Heart Clinic Mansfield, Ohio, United States, 44906 收起 <<
NCT00719914	-		Terminated(Poor enrollment)	-	-
NCT00812435	Myocardial Infarction	Phase 3	Terminated	-	United States, District of Col... 展开 >>umbia Washington Hospital Center Washington, District of Columbia, United States, 20010 收起 <<
NCT00945308	Acute Myocardial Infarction	Phase 2	Unknown	February 2010	Israel ... 展开 >> Assaf Harofeh Medical Center Not yet recruiting Beer Yakov, Israel, 70300 Contact: Alberto Hendler, MD +9726467757 ahendler@asaf.health.gov.il Principal Investigator: Alberto Hendler, MD 收起 <<
NCT00894803	Ischemic Stroke ... 展开 >> Stroke Brain Infarction 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> UCLA Ronald Reagan Medical Center Los Angeles, California, United States, 90024 University of California San Diego San Diego, California, United States, 92103 UCLA Medical Center Santa Monica Santa Monica, California, United States, 90404 United States, District of Columbia Washington Hospital Center Washington, District of Columbia, United States, 20010 United States, Kentucky St. Elizabeth Healthcare Edgewood Edgewood, Kentucky, United States, 41017 St. Elizabeth Healthcare Florence Florence, Kentucky, United States, 41042 St. Elizabeth Healthcare Ft. Thomas Ft. Thomas, Kentucky, United States, 41075 United States, Maryland Suburban Hospital Bethesda, Maryland, United States, 20814 United States, Michigan University of Michigan Medical Center Ann Arbor, Michigan, United States, 48109 United States, New Jersey Robert Wood Johnson University Hospital New Brunswick, New Jersey, United States, 08903 United States, North Carolina Mission Hospital, Inc. Asheville, North Carolina, United States, 28801 United States, Ohio The Christ Hospital Cincinnati, Ohio, United States, 45219 University Hospital Cincinnati, Ohio, United States, 45219 Good Samaritan Hospital Cincinnati, Ohio, United States, 45220-2489 The Jewish Hospital Cincinnati, Ohio, United States, 45236 Mercy Hospital, Western Hills Cincinnati, Ohio, United States, 45238 Mercy Hospital Mt Airy Cincinnati, Ohio, United States, 45239 Bethesda North Hospital Cincinnati, Ohio, United States, 45242 United States, Pennsylvania Hospital of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 United States, West Virginia West Virginia University Hospital Morgantown, West Virginia, United States, 26506 收起 <<
NCT00894803	-		Completed	-	-
NCT00834899	Sickle Cell Disease	Phase 1 Phase 2	Terminated(Slow accrual and no... 展开 >> cost extension not approved by NHLBI) 收起 <<	-	United States, North Carolina ... 展开 >> University of North Carolina Chapel Hill, North Carolina, United States, 27599-7305 收起 <<
NCT02204852	Septic Shock	Phase 2	Completed	-	Denmark ... 展开 >> Department of Anesthesia and Intensive Care, Nordsjællands Hospital Hillerød, Capital Region, Denmark, DK-3400 收起 <<
NCT01863134	-		Completed	-	-
NCT02925923	Acute Coronary Syndrome ... 展开 >> Angina, Unstable 收起 <<	Phase 2	Recruiting	December 2023	United States, Alabama ... 展开 >> University of Alabama Recruiting Birmingham, Alabama, United States, 35294 Principal Investigator: Massoud Leesar, MD 收起 <<
NCT00834899	-		Terminated(Slow accrual and no... 展开 >> cost extension not approved by NHLBI) 收起 <<	-	-
NCT01919723	Acute Coronary Syndrome	Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama Birmingham, Alabama, United States, 35294 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45267 收起 <<
NCT01919723	-		Completed	-	-
NCT01454440	Coronary Artery Disease	Phase 4	Terminated(The study was stopp... 展开 >>ed prematurely due to slow enrolment without code breaking.) 收起 <<	-	Italy ... 展开 >> University of Turin Turin, TO, Italy, 10126 收起 <<
NCT01977456	Stroke Brain ... 展开 >>Infarction 收起 <<	Phase 2	Completed	-	United States, Kentucky ... 展开 >> St. Elizabeth Healthcare System Edgewood Edgewood, Kentucky, United States, 41017 St. Elizabeth Healthcare Florence Florence, Kentucky, United States, 41042 St. Elizabeth Healthcare Ft. Thomas Ft. Thomas, Kentucky, United States, 41075 United States, Ohio The Christ Hospital Cincinnati, Ohio, United States, 45219 University of Cincinnati Medical Center Cincinnati, Ohio, United States, 45219 Good Samaritan Hospital Cincinnati, Ohio, United States, 45220 Jewish Hospital Cincinnati, Ohio, United States, 45236 Bethesda North Hospital Cincinnati, Ohio, United States, 45242 收起 <<
NCT01977456	-		Completed	-	-

Eptifibatide/依替巴肽 {[allProObj[0].p_purity_real_show]}

Eptifibatide/依替巴肽纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Eptifibatide/依替巴肽质控信息

Eptifibatide/依替巴肽生物活性

Eptifibatide/依替巴肽动物研究

Eptifibatide/依替巴肽临床研究

Eptifibatide/依替巴肽参考文献

Eptifibatide/依替巴肽实验方案

Eptifibatide/依替巴肽技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Eptifibatide/依替巴肽 {[allProObj[0].p_purity_real_show]}

Eptifibatide/依替巴肽 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Eptifibatide/依替巴肽 质控信息

Eptifibatide/依替巴肽 生物活性

Eptifibatide/依替巴肽 动物研究

Eptifibatide/依替巴肽 临床研究

Eptifibatide/依替巴肽 参考文献

Eptifibatide/依替巴肽 实验方案

Eptifibatide/依替巴肽 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Eptifibatide/依替巴肽纯度/质量文件产品仅供科研

Eptifibatide/依替巴肽质控信息

Eptifibatide/依替巴肽生物活性

Eptifibatide/依替巴肽动物研究

Eptifibatide/依替巴肽临床研究

Eptifibatide/依替巴肽参考文献

Eptifibatide/依替巴肽实验方案

Eptifibatide/依替巴肽技术信息